Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Pyrimidines Stories

2013-05-08 08:30:20

WAYNE, N.J., May 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American Thoracic Society (ATS) International Conference May 17 - 22, in Philadelphia, PA. "We are pleased that multiple new data sets from our riociguat clinical development program in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension were accepted for...

Leukemia Drug Prices Too Costly
2013-04-27 06:38:21

redOrbit Staff & Wire Reports - Your Universe Online More than 100 influential oncologists from over 15 different countries have joined forces to demand pharmaceutical companies reduce the prices of potentially life-saving cancer medication, some of which can cost patients in excess of $100,000 per year. In a commentary published Thursday by Blood, the journal of the American Society of Hematology, 120 doctors and researchers specializing in the treatment of chronic myeloid leukemia...

2013-04-08 04:20:47

WAYNE, N.J., April 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH). Both CTEPH and PAH are...

2013-04-05 16:23:26

A Live Telephone/Web Education Program Offering Live Spanish Interpretation Featuring International CML Expert Jorge Cortes, MD WHITE PLAINS, N.Y., April 5, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish-speaking patients with chronic myeloid leukemia (CML). On Wednesday, April 17, from 1:00 to 2:00 PM Eastern...

2013-02-14 08:30:16

WILMINGTON, Del., Feb. 14, 2013 /PRNewswire/ -- A survey conducted by AstraZeneca (NYSE: AZN) of more than 2000 American adults reveals that only 1 in 5 (20 percent) respondents consider themselves at increased risk for atherosclerosis-a progressive disease where plaque builds up in the arteries slowly over time.*( )The survey also revealed that only 21 percent of respondents could correctly identify all 6 surveyed atherosclerosis risk factors (high cholesterol, high blood pressure, diabetes,...

2013-02-13 10:34:36

Among pregnant women in sub-Saharan Africa, intermittent preventive therapy for malaria with 3 or more doses of the drug regimen sulfadoxine-pyrimethamine was associated with a higher birth weight and lower risk of low birth weight than the current standard 2-dose regimen, according to a review and meta-analysis of previous studies published in the February 13 issue of JAMA. "Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is used in 37...

2013-02-11 08:25:27

WAYNE, N.J., Feb. 11, 2013 /PRNewswire/ -- Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for riociguat, an investigational compound for the treatment of pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH. "Bayer is submitting an NDA for riociguat for the treatment of two...

2013-02-05 12:27:40

MISSISSAUGA, ON, Feb. 5, 2013 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) (the "Company" or "YM") is pleased to announce that the Supreme Court of Nova Scotia has issued a final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Gilead Sciences, Inc. ("Gilead") and 3268218 Nova Scotia Limited, a wholly-owned subsidiary of Gilead (the "Purchaser").   Under the Arrangement, the Purchaser will acquire all of the...

2013-01-31 12:28:29

MISSISSAUGA, ON, Jan. 31, 2013 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) (the "Company" or "YM") is pleased to announce that, at the special meeting (the "Meeting") of shareholders of the Company (the "YM Shareholders") held earlier today, the YM Shareholders approved the previously announced plan of arrangement (the "Arrangement") involving the Company, Gilead Sciences, Inc. ("Gilead") and 3268218 Nova Scotia Limited, a wholly-owned subsidiary of Gilead (the...

2013-01-26 23:02:25

Hair loss product at provillushairclub.com is now offered in maximum strength online. This topical spray solution is one of the only products now sold in a maximum strength formula to help men target hair loss and regrow hair again. Seattle, Washington (PRWEB) January 27, 2013 Hair loss is one of the most common conditions in men that can occur naturally or unnaturally due to certain circumstances. A variety of treatment options exists for men to regrow hair and the...